Considering microorganisms and New Genomic Techniques: on the need for a new GMO legislation in the European Union


European Week Against Cancer 2022 – Interview with Santiago Aguirre, Market Lead Europe Oncology, Sanofi


Big Changes Start Small


Opinion: A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare


EuropaBio response to the Call for Evidence on Soil health – protecting, sustainably managing and restoring EU soils


EuropaBio Statement on Rare Disease Day


EUBA position on the JRC LCA Methodology


The review of the general pharmaceutical legislation: an opportunity that should not be missed?


What is the use of innovation if it cannot be implemented? Or why consumers have the last word


EuropaBio Comments on the Roadmap on a Policy Framework on Biobased, Biodegradable and Compostable Plastics


EuropaBio response to the public consultation on the roadmap on Sustainable Food Systems


EuropaBio Response to the Inception Impact Assessment for Legislation for Plants Produced from Certain New Genomic Techniques (NGTs)


EuropaBio Comments on the Roadmap on Restoring Sustainable Carbon Cycles


Artificial intelligence: investing in new technologies in healthcare

What if machine learning and artificial intelligence could learn to detect one of the most common forms of blood cancer, through evaluating data based on the gene activity of blood cells?

EuropaBio response to the Public consultation on European bioeconomy policy: stocktaking and future developments

EuropaBio comments on the public consultation on blue bioeconomy.

EuropaBio comments on the public consultation on blue bioeconomy

EuropaBio comments on the public consultation on blue bioeconomy.

A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.

Enabling NGT products to contribute to sustainability: The role of Industrial Biotechnology


Decentralised clinical trials, the future of clinical research

The COVID-19 pandemic has been a catalyst for change which has led us to revisit the way we conduct clinical trials.

EuropaBio comments on the designation of official laboratories for animal and plant health and safe food and feedstuffs

EuropaBio comments on the draft delegated act on climate-related objectives under the Taxonomy Regulation.
Become a member